Overview of Iron Chelation Therapy with Desferrioxamine and Deferiprone

Chronic iron overload from frequent blood transfusions to treat patients with severe anemias leads to significant morbidity and mortality. Although desferrioxamine, the current standard of care, is an effective iron chelator with long-term evidence, it requires tedious subcutaneous infusion that reflects negatively on patient compliance. Deferiprone opened the horizon for an era of oral iron chelators. Although collective evidence proved its efficacy, safety issues are still of high concern and require regular monitoring. The experience with these two drugs helps better delineate the optimal goals of iron chelation therapy and the ideal iron chelator.

[1]  P. Moraitis,et al.  The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study , 2009, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[2]  G. D’Amico,et al.  Long‐term sequential deferiprone–deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial , 2009, British journal of haematology.

[3]  M. Cappellini,et al.  Guidelines for the Clinical Management of Thalassaemia , 2008 .

[4]  G. Spanos,et al.  Comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with β-thalassemia major , 2007 .

[5]  E. Vichinsky,et al.  Phase Ib clinical trial of starch‐conjugated deferoxamine (40SD02): a novel long‐acting iron chelator , 2007, British journal of haematology.

[6]  D. Pennell,et al.  A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance , 2007, Circulation.

[7]  A. Christoforidis,et al.  Four‐year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with β‐thalassaemia major: comparison between different chelation regimens , 2007, European journal of haematology.

[8]  G. Spanos,et al.  comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with beta-thalassemia major. , 2007, International journal of hematology.

[9]  M. Cappellini,et al.  Thalassemia intermedia: revisited. , 2006, Blood cells, molecules & diseases.

[10]  Mark A Westwood,et al.  Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. , 2006, Blood.

[11]  A. Cnaan,et al.  Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. , 2006, Blood.

[12]  A. Cohen,et al.  New advances in iron chelation therapy. , 2006, Hematology. American Society of Hematology. Education Program.

[13]  E. Alexopoulou,et al.  Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. , 2006, Blood cells, molecules & diseases.

[14]  D. Pennell,et al.  A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy with Deferoxamine and Deferiprone on Myocardial Iron in Thalassaemia Major Using Cardiovascular Magnetic Resonance. , 2005 .

[15]  Z. Cabantchik,et al.  LPI-labile plasma iron in iron overload. , 2005, Best practice & research. Clinical haematology.

[16]  D. Pennell,et al.  Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance , 2004, British journal of haematology.

[17]  G. Kontoghiorghes,et al.  The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. , 2004, Current medicinal chemistry.

[18]  P. Jarritt,et al.  Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. , 2004, Blood.

[19]  E. Neufeld,et al.  Complications of beta-thalassemia major in North America. , 2004, Blood.

[20]  G. Sanna,et al.  Iron overload and desferrioxamine chelation therapy in β-thalassemia intermedia , 1981, European Journal of Pediatrics.

[21]  A. Cnaan,et al.  Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. , 2004, Haematologica.

[22]  R. Galanello,et al.  Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. , 2003, Blood.

[23]  A. Hoffbrand,et al.  Clinical trial of deferiprone iron chelation therapy in β‐thalassaemia/haemoglobin E patients in Thailand , 2003, British journal of haematology.

[24]  A. Hoffbrand,et al.  Role of deferiprone in chelation therapy for transfusional iron overload. , 2003, Blood.

[25]  A. Hoffbrand,et al.  Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients , 2003, British journal of haematology.

[26]  A. Piga,et al.  Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. , 2003, Haematologica.

[27]  D. Pennell,et al.  Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia , 2002, The Lancet.

[28]  G. D’Amico,et al.  Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. , 2002, Blood cells, molecules & diseases.

[29]  Matthew Darlison,et al.  Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register , 2000, The Lancet.

[30]  J. Porter,et al.  Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia , 2000 .

[31]  J. Porter,et al.  Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. , 2000, Blood.

[32]  N. Olivieri The β-Thalassemias , 1999 .

[33]  Wright,et al.  Combined therapy with deferiprone and desferrioxamine , 1998, British journal of haematology.

[34]  K. Fleming,et al.  Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. , 1998, The New England journal of medicine.

[35]  M. Cappellini,et al.  Survival and Disease Complications in Thalassemia Major , 1998, Annals of the New York Academy of Sciences.

[36]  G. Brittenham,et al.  Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.

[37]  C. Borgna-Pignatti,et al.  Evaluation of a new method of administration of the iron chelating agent deferoxamine. , 1997, The Journal of pediatrics.

[38]  A. Piga,et al.  Results of long-term iron-chelating therapy. , 1996, Acta haematologica.

[39]  G. Kontoghiorghes Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs. , 1995, Toxicology letters.

[40]  G. Koren,et al.  Iron-chelation therapy with oral deferiprone in patients with thalassemia major. , 1995, The New England journal of medicine.

[41]  G. Kontoghiorghes New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review. , 1995, The Analyst.

[42]  A. Bartlett,et al.  Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes. , 1995, Arzneimittel-Forschung.

[43]  J. H. MacMillan,et al.  Survival in Medically Treated Patients with Homozygous β-Thalassemia , 1994 .

[44]  G. Koren,et al.  Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. , 1994, Blood.

[45]  J. H. MacMillan,et al.  Survival in medically treated patients with homozygous beta-thalassemia. , 1994, The New England journal of medicine.

[46]  R. Abeysinghe,et al.  Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[47]  R. Puniyani,et al.  Long‐term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial , 1992, British journal of haematology.

[48]  I. Adamson,et al.  Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning , 1992, The Lancet.

[49]  G. Koren,et al.  Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. , 1992, Blood.

[50]  G. Koren,et al.  Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients , 1990, The Lancet.

[51]  A. Hoffbrand,et al.  Long‐term trial with the oral iron chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one (L1) I. IRON CHELATION AND METABOLIC STUDIES , 1990, British journal of haematology.

[52]  G. Kontoghiorghes,et al.  Pharmacokinetic studies in humans with the oral iron chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one , 1990, Clinical pharmacology and therapeutics.

[53]  K. Konstantopoulos,et al.  Acute Bone Marrow Aplasia Associated with Intravenous Administration of Deferoxamine (Desferrioxamine) , 1990, Drug safety.

[54]  D. Weatherall,et al.  Iron balance and the management of iron overload in beta-thalassemia intermedia. , 1988, Birth defects original article series.

[55]  S. Underwood,et al.  DESFERRIOXAMINE TO IMPROVE CARDIAC FUNCTION IN IRON-OVERLOADED PATIENTS WITH THALASSAEMIA MAJOR , 1984, The Lancet.

[56]  S. De Virgiliis,et al.  Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia. , 1981, European journal of pediatrics.

[57]  A. Marty,et al.  Recovery from non-traumatic localised gas gangrene and clostridial septicaemia. , 1969, Lancet.

[58]  H. Keberle The Biochemistry of Desferrioxamine and its Relation to Iron Metabolism , 1964, Annals of the New York Academy of Sciences.